<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02228473</url>
  </required_header>
  <id_info>
    <org_study_id>CRBDGlycoAtr</org_study_id>
    <nct_id>NCT02228473</nct_id>
  </id_info>
  <brief_title>Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort</brief_title>
  <official_title>Effect of Glycopyrrolate and Atropine as Adjuncts to Reversal of Non-Depolarizing Neuromuscular Blocking Agents on Postoperative Catheter-Related Bladder Discomfort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of
      catheter-related bladder discomfort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanism of catheter-related bladder discomfort is thought to be related to the
      muscarinic receptor. The adjuncts to reversal agents such as glycopyrrolate and atropine are
      known to block the muscarinic receptor in different ways.

      We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of
      catheter-related bladder discomfort.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Catheter-related bladder discomfort</measure>
    <time_frame>1 hour postoperatively</time_frame>
    <description>Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catheter-related bladder discomfort</measure>
    <time_frame>0, 6 and 24 hour postoperatively</time_frame>
    <description>Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic parameters</measure>
    <time_frame>0, 1, 5, 10 minute postoperatively</time_frame>
    <description>Mean blood pressure and heart rate will be measured at 0, 1, 5, 10 minute postoperatively. Measurement at 10 minute means Mean blood pressure and heart rate at the admission of post-anesthetic care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>0, 1, 6 and 24 hour postoperatively</time_frame>
    <description>Nausea will be measured at 0, 1, 6 and 24 hour postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>0, 1, 6 and 24 hour postoperatively</time_frame>
    <description>Vomiting will be measured at 0, 1, 6 and 24 hour postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry mouth</measure>
    <time_frame>0, 1, 6 and 24 hour postoperatively</time_frame>
    <description>Dry mouth will be measured at 0, 1, 6 and 24 hour postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flushing</measure>
    <time_frame>0, 1, 6 and 24 hour postoperatively</time_frame>
    <description>Flushing will be measured at 0, 1, 6 and 24 hour postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blurred vision</measure>
    <time_frame>0, 1, 6 and 24 hour postoperatively</time_frame>
    <description>Blurred vision will be measured at 0, 1, 6 and 24 hour postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizziness</measure>
    <time_frame>0, 1, 6 and 24 hour postoperatively</time_frame>
    <description>Dizziness will be measured at 0, 1, 6 and 24 hour postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesics</measure>
    <time_frame>0, 1, 6 and 24 hour postoperatively</time_frame>
    <description>The amount of analgesics will be measured at 0, 1, 6 and 24 hour postoperatively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Catheter Site Discomfort</condition>
  <condition>Complications</condition>
  <condition>Anesthesia</condition>
  <condition>Urinary Bladder Neoplasms</condition>
  <arm_group>
    <arm_group_label>Glycopyrrolate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atropine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Glycopyrrolate will be administered.</description>
    <arm_group_label>Glycopyrrolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>Atropine will be administered.</description>
    <arm_group_label>Atropine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for transurethral bladder excision under general anesthesia

          -  ASA I-III

        Exclusion Criteria:

          -  Foley catheter less than 18 Fr.

          -  Patients with obstruction of urinary tract

          -  Patients with neurogenic bladder

          -  Patients with severe obesity

          -  Patients with neurologic disorder

          -  Patients with chronic pain

          -  Patients with allergic history to atropine or glycopyrrolate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee-Pyoung Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University of Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Chang Kim, MD</last_name>
    <phone>82-10-2886-2876</phone>
    <email>onidori1979@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University of Hospital</name>
      <address>
        <city>Seoul, Korea, Republic of</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee-Pyoung Park, PhD</last_name>
      <phone>+82-10-2971-7647</phone>
      <email>hppark@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hyun-Chang Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hee-Pyoung Park, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2014</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Neuromuscular Blocking Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

